Company Spotlight: Abivax

Abivax is the kind of company that makes markets nervous because it refuses to behave like a story stock. It was born in December 2013 out of three French biotechs stitched together by Truffle Capital in Paris, with Philippe Pouletty betting that immune balance would matter more than immune suppression. For years, Abivax moved quietly, working on antivirals, learning the hard way, taking punches in public markets, and building real science while most people stopped paying attention.

The turn came in a Montpellier lab when obefazimod, first designed for HIV, showed something else entirely. By enhancing microRNA-124, it did not silence one inflammatory signal. It restored order across several at once. IL-6, IL-17, TNF-α, IL-22, all pulled back into line. That discovery, guided by Professor Jamal Tazi and later clinically led by Professor Séverine Vermeire, turned a detour into a destination. Ulcerative colitis was not an accident. It was an opening.

The company nearly ran out of oxygen in 2019. Shares were down hard after the 2015 IPO. Cash was thin. Sofinnova Partners stepped in with a €12 million investment, led by Kinam Hong, not because it sounded good, but because the Phase 2 data did. That decision aged well. In July 2025, Abivax dropped Phase 3 results across more than 1,200 patients, including the largest JAK-inhibitor non-responder population ever studied in UC. Obefazimod delivered statistically significant remission, response, endoscopic improvement, and clean safety. The stock reacted the way markets do when they realize they were late.

Leadership matters at moments like this. Marc de Garidel took over as Chief Executive Officer in May 2023, bringing scars and wins from Ipsen, Corvidia Therapeutics, and CinCor Pharma. Sylvie Grégoire became Chair in July 2024, adding global commercial judgment. Fabio Cataldi runs medicine with a résumé shaped at Arena, AbbVie, and Landos. Didier Blondel keeps the balance sheet tight. Ida Hatoum builds the people engine. David Birnbaum watches the data like a hawk. Pierre Courteille thinks in markets, not slogans. This is not a hope crew. It is an execution crew.

With roughly $700 million in net proceeds raised in July 2025, runway into 2027, maintenance data coming in 2026, and regulatory filings lined up, Abivax is moving from proof to pressure. They are hiring, scaling, and building toward something that feels durable. The question now is not whether the signal was real. It is who is paying attention early enough to matter.